Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
LFW Photonics Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by SciSparc Ltd
< Previous
1
2
Next >
Weight Loss Treatment: SciSparc’s Obesity Drug Showed Positive Results in a Pre-Clinical Trial
December 01, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Adopts Limited Duration Shareholder Rights Plan
November 28, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
November 28, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
November 27, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
New Hope for Children: SciSparc's patented CBD- Enhanced Solution for Autism Spectrum Disorder
November 24, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel
November 22, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Celebrates Major Breakthrough: Positive Results Show its Treatment has a Remarkable Impact on Alzheimer's Agitation
November 15, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Aims to Change Tourette Syndrome Treatments; Will Start a Phase IIb Trial with its Innovative Pharma-Grade THC-Based Medication
November 10, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Granted Patent from the Australian Patent Office for its Reduction of Opioids Use in Pain Management Technology
October 31, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Granted Patent for its Core Technology From the Australian Patent Office
October 24, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification
October 16, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Ltd. Announces Closing of $5.026 Million Private Placement
October 13, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement
October 11, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Granted European Patent for its Core Technology
October 03, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder
September 29, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
September 27, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Announces 1-for-26 Reverse Share Split
September 20, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities
September 12, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
September 07, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
September 07, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Ltd. Closes $1.3 Million Underwritten Public Offering
August 14, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
August 10, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Ltd. Announces Proposed Underwritten Public Offering of Approximately $1.3 Million
August 09, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.
August 01, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
SPRC
SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
July 14, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
June 30, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome
June 21, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome
June 16, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
SPRC
SciSparc Grants an Exclusive License for the Sales of CannAmide™ on the Amazon Marketplace in Canada to SciSparc Nutraceuticals
June 07, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial
June 02, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.